Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
REGULATORY
Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
Quick Look: Three NMEs are set for approval review by an MHLW panel on May 29: Biogen’s diroximel fumarate, Santen’s netarsudil, and Sanofi’s rilzabrutinib. The agenda also includes Wegovy’s proposed MASH expansion, additional indications for Avastin and Sogroya, and pediatric…
To read the full story
Related Article
- Novo’s Wegovy Nears Japan Approval as First MASH Therapy
June 1, 2026
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
- Chugai Seeks Avastin Label Expansion for Neurofibromatosis Type 2
September 25, 2025
- Novo Japan Files Sogroya for SGA-Related and Noonan Syndrome Short Stature
July 31, 2025
- Santen Files Glaucoma Drug Rhopressa in Japan
July 31, 2025
REGULATORY
- Japan Nudged to Probe Wide Gaps in Biosimilar Uptake
November 6, 2026
- Japan Eyes Multi-Year Investment Support for Wholesalers in FY2027 Budget
November 6, 2026
- Japan Issues Guidance on AI Model Use in Drug Manufacturing, Quality Control
November 6, 2026
- JPMA Urges Foreign Price Rule Overhaul to Address US MFN Policy: LDP Hearing
November 5, 2026
- MOF Presses for Full FY2027 Drug Price Revision Without Price Gap Thresholds
November 4, 2026
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…